S-3 GROUP

Lobbying for ORCHARD THERAPEUTICS NORTH AMERICA · Biotech company

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · Massachusetts · House · Senate · $80,000.00 income · posted Jan 15, 2026

Lobbying activity 2

Budget/Appropriations

Issues related to funding for newborn screenings for metachromatic leukodystrophy

Medical/Disease Research/Clinical Labs

Issues related to funding for newborn screenings for metachromatic leukodystrophy

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.